April 27, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) shares over potential securities laws violations by Ampio Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) concerning whether a series of statements by Ampio Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Ampio Pharmaceuticals Inc reported that its annual Net Loss increased from $11.59 million in 2012 to $38.13 million in 2014. Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) grew from $3.26 per share in late 2014 to as high as $8.61 per share in March 2015.

Then on April 20, 2015 Ampio Pharmaceuticals Inc announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion (WOMAC A: p < 0.001).

Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) declined to as low as $2.49 per share on April 20, 2015.